Home

Novo Nordisk A/S Common Stock (NVO)

68.24
+0.00 (0.00%)
NYSE · Last Trade: Apr 3rd, 6:51 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Why Hims & Hers Health Stock Couldn't Beat the Market Todayfool.com
Via The Motley Fool · April 2, 2025
Hims Dives After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitchinvestors.com
It's true, the company can sell Lilly's tirzepatide. But that doesn't mean patients will buy it.
Via Investor's Business Daily · April 2, 2025
Novo Nordisk Stakeholder Reports $9 Billion In Income Due To Robust Weight Loss Drug Salesbenzinga.com
Novo Nordisk saw its stock drop 21% year-to-date, pressured by weaker-than-expected obesity drug trial results.
Via Benzinga · April 2, 2025
Novo Nordisk’s Controlling Shareholder Novo Holdings Reports Record Total Income, Investment Returns In 2024: Retail Stays Bullishstocktwits.com
The company said that its earnings consist of income from dividends and the share repurchase programmes of Novo Group companies Novo Nordisk A/S and Novonesis A/S, as well as returns from its investment portfolio.
Via Stocktwits · April 2, 2025
Viking Therapeutics, Down 40%, Just Reached a New Milestone. Is the Stock a Buy Now?fool.com
Via The Motley Fool · April 2, 2025
Hims & Hers Health Stock Jumped Tuesday Afternoon: What Happened?benzinga.com
Hims & Hers Health Inc (NYSE:HIMS) shares spiked higher in afternoon trading Tuesday after the company said it will offer Eli Lilly And Co's (NYSE:LLY) Zepbound through its Telehealth platform.
Via Benzinga · April 1, 2025
Hims Stock Rockets After Inking Deal To Sell Eli Lilly's Obesity Drug, Zepboundinvestors.com
The deal allows Hims & Hers to sell Eli Lilly's Zepbound on its telehealth platform.
Via Investor's Business Daily · April 1, 2025
10 Health Care Stocks With Whale Alerts In Today's Sessionbenzinga.com
Via Benzinga · April 1, 2025
Novo Nordisk Shares Data From Injectable Ozempic, Oral Weight Loss Drugbenzinga.com
Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL trial finds Rybelsus lowers cardiovascular risk by 14%.
Via Benzinga · March 31, 2025
Which Healthcare Stock Is the Best Buy Right Now?
Healthcare stocks provide a combination of upstarts with a high risk, high reward proposition to established firms that can be a defensive maneuver.
Via MarketBeat · March 31, 2025
US Stocks Likely To Open Lower After 3-Day Fall: 'Equity Drawdown Probability Hasn't Peaked Yet,' Says Goldman Sachs Analystbenzinga.com
U.S. stock futures fell on Monday after three consecutive days of decline on Friday. Futures of benchmark indices were lower in premarket.
Via Benzinga · March 31, 2025
While Wall Street Panicked, These 3 Hidden Small-Caps Exploded Last Week — One Surging A Jaw-Dropping 60%benzinga.com
As uncertainties surrounding trade policies, fresh recession fears, and persistent inflation kept the markets on tenterhooks throughout the past week, a handful of small-caps defied the odds by posting significant gains.
Via Benzinga · March 31, 2025
Competitive Analysis In The ATTR-CM Fieldtalkmarkets.com
Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the ATTR-CM market in the next 3 years.
Via Talk Markets · March 30, 2025
Is Hims & Hers Stock Too Cheap to Pass Up?fool.com
This high-growth stock may be cheaper than you think.
Via The Motley Fool · March 29, 2025
Benzinga Bulls And Bears: Chevron, Microsoft, Nike — And Tariffs Have Automotive Sector Reelingbenzinga.com
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Via Benzinga · March 29, 2025
Deal Dispatch: Bezos-Backed Crop Company Wilts, Tech Startup Nabs Napster For $207 Millionbenzinga.com
AT&T, Searchlight Capital Partners, Blackstone, I Squared Capital, and Morgan Stanley are all actively seeking to ink a deal.
Via Benzinga · March 28, 2025
Novo Nordisk Stock Slips After BofA, Morgan Stanley Slash Price Targets – But Retail Goes Contrarianstocktwits.com
Bank of America analysts said Novo Nordisk might miss first-quarter estimates. According to TheFly, they expect the company to lower its full-year sales guidance from 16%-24% at constant exchange rates to 14%-22%.
Via Stocktwits · March 28, 2025
Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1investors.com
The company is looking for drugs it can add to Wegovy to improve the amount of weight lost.
Via Investor's Business Daily · March 28, 2025
Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordiskbenzinga.com
Lexicon Pharmaceuticals granted Novo Nordisk exclusive rights to develop LX9851, an oral obesity drug, with potential milestone payments of up to $1 billion.
Via Benzinga · March 28, 2025
Is Hims & Hers Health Stock a Smart Buy After Plunging More Than 50%?fool.com
Via The Motley Fool · March 28, 2025
Why Novo Nordisk Stock Dipped on Thursdayfool.com
Via The Motley Fool · March 27, 2025
1 Growth Stock Down 40% to Buy and Hold Foreverfool.com
Via The Motley Fool · March 27, 2025
Looking for growth without the hefty price tag? Consider NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO).chartmill.com
Based on Fundamental Analysis it can be said that NYSE:NVO is a growth stock which is not overvalued.
Via Chartmill · March 27, 2025
Novo Nordisk Stock Sinks To 52-Week Lows: Weight Loss Boom Losing Steam?benzinga.com
Novo Nordisk is betting on the future with a $2-billion deal to buy rights to a Chinese obesity drug. But investors remain unimpressed.
Via Benzinga · March 26, 2025
EXCLUSIVE: Vivani Medical Subdermal Semaglutide Implant Shows 20% Weight Loss In Animal Study, With Potential For Once-Yearly Dosingbenzinga.com
Vivani Medical's NPM-139 semaglutide implant showed steady drug release and nearly 20% weight loss in preclinical studies, supporting long-term weight management.
Via Benzinga · March 26, 2025